{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:33:01Z","timestamp":1793878381395,"version":"4.7.0"},"reference-count":37,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Waldenstrom\u2019s Macroglobulinemia (WM) is a heterogeneous disease, and the majority of patients tend to have a long course. Nevertheless, it is imperative to detect patients who have a high risk of progression and who benefit from closer follow-up. Many recent studies have displayed the CD163-positive tumor-associated macrophages (TAMs) contribution in the pathogenesis of various hematological neoplasms and solid tumors. Soluble CD163 (sCD163) can be measured in serum, along with other TAM-chemoattractant cytokines, such as CCL2 and CCL4, and their levels are used to determine macrophage activation. In the current study, we investigated the correlation between sCD163, CCL2, and CCL4, with parameters of WM progression and survival. Out of a total of 204 WM patients, serum sCD163, CCL2, and CCL4 were measured in 75, 64, and 65 patients\u2019 frozen sera at diagnosis, along with 30 healthy individuals (HIs) using an enzyme-linked immunosorbent assay (ELISA). We achieved to demonstrate that shorter Time to Treatment (TTT) was observed in 2 years and 7 years intervals in all patients with a ratio of CD163\/CCL4 above median (p = 0.003 and p = 0.024, respectively) and decreased TTT was observed in all asymptomatic WM (AWM) patients with values of CCL4 above the median (p = 0.018). Moreover, significantly decreased overall survival (OS) (p = 0.033) was observed in all WM patients with CCL2 values above the median. Our results indicate that sCD163, CCL2, and CCL4 could be utilized as prognostic markers in WM.<\/jats:p>","DOI":"10.3390\/cells14040275","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T10:36:58Z","timestamp":1739443018000},"page":"275","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tumor-Associated Macrophage (TAM)-Related Cytokines, sCD163, CCL2, and CCL4, as Novel Biomarkers for Overall Survival and Time to Treatment in Waldenstrom\u2019s Macroglobulinemia: Emphasis on Asymptomatic WM"],"prefix":"10.3390","volume":"14","author":[{"given":"Alexandros","family":"Gkiokas","sequence":"first","affiliation":[{"name":"Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mavra","family":"Papadatou-Gigante","sequence":"additional","affiliation":[{"name":"Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1599-5509","authenticated-orcid":false,"given":"Annita Ioanna","family":"Gkioka","sequence":"additional","affiliation":[{"name":"Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3284-3710","authenticated-orcid":false,"given":"Aspasia","family":"Koudouna","sequence":"additional","affiliation":[{"name":"Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomai M.","family":"Tryfou","sequence":"additional","affiliation":[{"name":"Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Alexandropoulos","sequence":"additional","affiliation":[{"name":"Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Bartzi","sequence":"additional","affiliation":[{"name":"Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolitsa","family":"Kafasi","sequence":"additional","affiliation":[{"name":"Immunology Department, Laikon Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Kyrtsonis","sequence":"additional","affiliation":[{"name":"Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1182\/blood.2019000725","article-title":"How I Treat Waldenstr\u00f6m Macroglobulinemia","volume":"134","author":"Dimopoulos","year":"2019","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clml.2017.02.028","article-title":"Waldenstr\u00f6m Macroglobulinemia: Review of Pathogenesis and Management","volume":"17","author":"Yun","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/BLCTT.S259860","article-title":"Differential Diagnosis of Waldenstr\u00f6m\u2019s Macroglobulinemia and Early Management: Perspectives from Clinical Practice","volume":"12","author":"Cingam","year":"2022","journal-title":"Blood Lymphat. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1182\/blood-2011-10-384768","article-title":"Progression in Smoldering Waldenstr\u00f6m Macroglobulinemia: Long-Term Results","volume":"119","author":"Kyle","year":"2012","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3816\/CLML.2011.n.017","article-title":"Differential Diagnosis of IgM MGUS and WM According to B-Lymphoid Infiltration by Morphology and Flow Cytometry","volume":"11","author":"Ocio","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/sonc.2003.50038","article-title":"Prognostic Markers and Criteria to Initiate Therapy in Waldenstrom\u2019s Macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia","volume":"30","author":"Kyle","year":"2003","journal-title":"Semin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3816\/CLM.2009.n.002","article-title":"IgM Monoclonal Gammopathy of Undetermined Significance and Smoldering Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"9","author":"Kyle","year":"2009","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Pan, Y., Yu, Y., Wang, X., and Zhang, T. (2020). Tumor-Associated Macrophages in Tumor Immunity. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.583084"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-Associated Macrophages: From Mechanisms to Therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-017-0430-2","article-title":"Tumor-Associated Macrophages: From Basic Research to Clinical Application","volume":"10","author":"Yang","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhou, J., Tang, Z., Gao, S., Li, C., Feng, Y., and Zhou, X. (2020). Tumor-Associated Macrophages: Recent Insights and Therapies. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00188"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cmi.2014.83","article-title":"The Origin and Function of Tumor-Associated Macrophages","volume":"12","author":"Liu","year":"2015","journal-title":"Cell. Mol. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00365513.2011.626868","article-title":"Soluble CD163","volume":"72","year":"2012","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1089\/ars.2012.4834","article-title":"CD163 and Inflammation: Biological, Diagnostic, and Therapeutic Aspects","volume":"18","author":"Etzerodt","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ejh.12296","article-title":"Monocyte\/Macrophage-Derived Soluble CD163: A Novel Biomarker in Multiple Myeloma","volume":"93","author":"Andersen","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cytogfr.2009.11.009","article-title":"CC Chemokine Ligand 2 (CCL2) Promotes Prostate Cancer Tumorigenesis and Metastasis","volume":"21","author":"Zhang","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3349\/ymj.2015.56.4.1134","article-title":"Chemokine Signaling Pathway Involved in CCL2 Expression in Patients with Rheumatoid Arthritis","volume":"56","author":"Zhang","year":"2015","journal-title":"Yonsei Med. J."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Jin, J., Lin, J., Xu, A., Lou, J., Qian, C., Li, X., Wang, Y., Yu, W., and Tao, H. (2021). CCL2: An Important Mediator Between Tumor Cells and Host Cells in Tumor Microenvironment. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.722916"},{"key":"ref_19","unstructured":"Crusio, W.E., Lambris, J.D., and Radeke, H.H. (2020). Tumor Microenvironment the Role of Chemokines\u2014Part A, Springer."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"De la Fuente L\u00f3pez, M., Landskron, G., Parada, D., Dubois-Camacho, K., Simian, D., Martinez, M., Romero, D., Roa, J.C., Chahu\u00e1n, I., and Guti\u00e9rrez, R. (2018). The Relationship between Chemokines CCL2, CCL3, and CCL4 with the Tumor Microenvironment and Tumor-Associated Macrophage Markers in Colorectal Cancer. Tumor Biol., 40.","DOI":"10.1177\/1010428318810059"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood-2008-07-172080","article-title":"Long-Term Survival in Waldenstrom Macroglobulinemia: 10-Year Follow-up of Southwest Oncology Group Directed Intergroup Trial S9003","volume":"113","author":"Dhodapkar","year":"2009","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3904\/kjim.2019.367","article-title":"Real-World Data on the Survival Outcome of Patients with Newly Diagnosed Waldenstr\u00f6m Macroglobulinemia","volume":"36","author":"Cho","year":"2021","journal-title":"Korean J. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3324\/haematol.12846","article-title":"The International Prognostic Scoring System for Waldenstr\u00f6m\u2019s Macroglobulinemia Is Applicable in Patients Treated with Rituximab-Based Regimens","volume":"93","author":"Dimopoulos","year":"2008","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/ajh.22027","article-title":"No Significant Improvement in the Outcome of Patients with Waldenstr\u00f6m\u2019s Macroglobulinemia Treated over the Last 25 Years","volume":"86","author":"Kastritis","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00277-001-0385-8","article-title":"Waldenstr\u00f6m Macroglobulinemia: Clinical Course and Prognostic Factors in 60 Patients. Experience from a Single Hematology Unit","volume":"80","author":"Kyrtsonis","year":"2001","journal-title":"Ann. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/ejh.13371","article-title":"Circulating extracellular vesicle-associated CD163 and CD206 in multiple myeloma","volume":"104","author":"Kvorning","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.7150\/jca.30102","article-title":"High Numbers of CD163+ Tumor-Associated Macrophages Correlate with Poor Prognosis in Multiple Myeloma Patients Receiving Bortezomib-Based Regimens","volume":"10","author":"Wang","year":"2019","journal-title":"J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-Associated Macrophages and Survival in Classic Hodgkin\u2019s Lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1158\/1078-0432.CCR-12-2693","article-title":"Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma","volume":"19","author":"Jones","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.3109\/10428194.2015.1026899","article-title":"Soluble CD163 as a Prognostic Biomarker in B-Cell Chronic Lymphocytic Leukemia","volume":"56","author":"Nederby","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.3324\/haematol.2020.278182","article-title":"Prognostic Impact of Soluble Cd163 in Patients with Diffuse Large B-Cell Lymphoma","volume":"106","author":"Vajavaara","year":"2021","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Koudouna, A., Gkioka, A.I., Gkiokas, A., Tryfou, T.M., Papadatou, M., Alexandropoulos, A., Bartzi, V., Kafasi, N., and Kyrtsonis, M.C. (2024). Serum-Soluble CD163 Levels as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma Treated with Chemoimmunotherapy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052862"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/1759-7714.12643","article-title":"High Levels of CCL2 or CCL4 in the Tumor Microenvironment Predict Unfavorable Survival in Lung Adenocarcinoma","volume":"9","author":"Li","year":"2018","journal-title":"Thorac. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3816\/CLML.2011.n.019","article-title":"CD138 Expression Helps Distinguishing Waldenstr\u00f6m\u2019s Macroglobulinemia (WM) from Splenic Marginal Zone Lymphoma (SMZL)","volume":"11","author":"Kyrtsonis","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2478\/rir-2021-0031","article-title":"Macroglobulinemia and Autoinflammatory Disease","volume":"2","author":"Yao","year":"2021","journal-title":"Rheumatol. Immunol. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.18632\/oncotarget.26946","article-title":"Targeting IL-6 Receptor Reduces IgM Levels and Tumor Growth in Waldenstr\u00f6m Macroglobulinemia","volume":"10","author":"Han","year":"2019","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1182\/blood-2011-04-351742","article-title":"Comprehensive Analysis of Tumor Microenvironment Cytokines in Waldenstrom Macroglobulinemia Identifies CCL5 as a Novel Modulator of IL-6 Activity","volume":"118","author":"Elsawa","year":"2011","journal-title":"Blood"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/4\/275\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:33:12Z","timestamp":1760027592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/4\/275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["cells14040275"],"URL":"https:\/\/doi.org\/10.3390\/cells14040275","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]}}}